A test for COVID-19 risk, infectivity and immunity
7 April 2020 Monash scientists are repurposing technology they developed recently to make a rapid test to determine who: has immunity to coronavirus remains infectious is at risk of developing a severe form of the disease. A team,…
Robert Bosch Australia – Manufacturers FOR Manufacturers
7 April 2020 Posted on behalf of Robert Bosch Australia in regards to COVID-19 assistance: “We are designers and builders of manual to automated manufacturing systems, robotics and testing systems which can be used in the manufacturing of anything…
Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
7 April 2020 Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) to develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with the investigational development of one,…
CSIRO – Nation’s disease response bolstered
4 April 2020 With the increasing threat of diseases spreading from animals to humans, including COVID-19, $220m will be directed to upgrading the high containment biosecurity research facility in Geelong, currently testing vaccines to combat the disease. Operated…
Call for Australian manufacturers to supply COVID-19 test kit components
6 April 2020 Are you an Australian manufacturer with the capability to produce inputs for COVID-19 RNA extraction? Do you have support to scale up your production? We want to hear from you. Securing Australia’s COVID-19 testing capacity…
Possible coronavirus drug identified by Monash University scientists
3 April 2020 A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint venture of the University of Melbourne and Royal Melbourne Hospital, has shown that…
Noxopharm Investigating Potential COVID-19 Treatment
1 April 2020 Noxopharm (NOX:ASX) announces that the Hudson Institute of Medical Research (Hudson Institute) in Melbourne has identified that idronoxil inhibits a key inflammatory pathway involved in a process known as a cytokine storm. Cytokine storm is…
Where are we at with developing a vaccine for coronavirus?
3 April 2020 This article is republished from The Conversation under a Creative Commons license. Read the original article. Shutterstock Kylie Quinn, RMIT University and Damian Purcell, The Peter Doherty Institute for Infection and Immunity SARS-CoV-2, the virus…
New international collaboration showcases drug development potential
3 April 2020 New research from Monash Institute of Pharmaceutical Sciences (MIPS), in collaboration with the Max Planck Institute, Mayo Clinic, University of Auckland, University of Essex and University of Tokyo, has uncovered new structures of protein receptors,…
CSIRO begins testing COVID-19 vaccines
2 April 2020 CSIRO, Australia’s national science agency, has commenced the first stage of testing potential vaccines for COVID-19. The testing, expected to take three months, is underway at CSIRO’s high-containment biosecurity facility, the Australian Animal Health Laboratory…
BCG vaccine trial to protect Australian healthcare workers has begun, enabled by major philanthropic backing
2 April 2020 News at a Glance The BRACE trial to test whether BCG vaccination reduces the impact of COVID-19 has begun in Melbourne 300 staff at the Melbourne Children’s Campus of the planned 4000 healthcare workers across…
Australians 65 and older become first in the world to access FLUAD® Quad
2 April 2020 Australians 65 and older have become the first in the world to access FLUAD® Quad (adjuvanted quadrivalent influenza vaccine) following addition to the National Immunisation Program in 2020(1) FLUAD® Quad is a new vaccine that…
